While GSK shares are largely unchanged following the deal announcement, CureVac shares have shot up by nearly 22%. Overall, the Street has a Moderate Buy consensus rating on CureVac. At the same time, the average CVAC price target of $10.25 implies a mouth-watering 206.9% potential upside in the stock.